Despite these pharmacologic limitations, EPZ5676 was investigated as a single-agent in a phase 1 clinical trial in relapsed/refractory MLL-rearranged AML (NCT01684150) [165]. This evidence concerns the gene KMT2A and acute myeloid leukemia.